PTO/SB/21 (09-04)
Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMR control number. **Application Number** 10/691.624 Filing Date October 24, 2003 HEGEIVER TRANSMITTAL CENTRAL FAX CENTER First Named Inventor Joachim BRENDEL et al. **FORM** Art Unit <del>JAN 17 2006</del> Examiner Name DESAL Rita J. (to be used for all correspondence after initial filing) Attorney Docket Number DEAV1999/L060 US NP 2 Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Drawing(s) Fee Transmittal Form Appeal Communication to Board Licensing-related Papers of Appeals and Interferences Fee Attached Appeal Communication to TC (Appeal Notice, Brief, Repty Brief) ٧ Petition Amendment/Reply Petition to Convert to a Proprietary Information Provisional Application After Final Power of Altomey, Revocation Status Letter Change of Correspondence Address Affidavits/declaration(s) Other Endosure(s) (please Identify Terminal Disclaimer below): Extension of Time Request Request for Refund Express Abandonment Request CD, Number of CD(s) Information Disclosure Statement Landscape Table on CD: Remarks Certified Copy of Priority Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name AVENTIS PHARMACEUTICALS INC. Signature Printed name Joseph D. Rossi Reg. No. Date 47,038 Jamuary 17, 2006 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mall in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on ; Total No. of Pages Transmitted: 21 the date shown below: (USPTO FAX NO. 571-273-8300 Signature Date January 17, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case, any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office. U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. On NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO. Commissioner for Patents P.O. Box 1450, Alexandria, VA 22313-1450. ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Typed or printed name

Paul Irvine

## DEAV1999/L060 US NP2

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

HEPEINED CENTRAL FAX CENTER

In re Application of

Examiner:

R. Desai

JAN 17 2006

BRENDEL, et al.

Art Unit:

1625

Application No.: 10/691,624

Filed:

October 24, 2003

Title:

2'-SUBSTITUTED 1, 1'-BIPHENYL-2-

CARBOXAMIDES, PROCESSES FOR THEIR PREPARATION, THEIR USE

AS MEDICAMENTS, AND **PHARMACEUTICAL** 

PREPARATIONS COMPRISING

THEM

TELEFAX CERTIFICATE

I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, Alexandria, VA 22313, on

January 17, 2006

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

## AMENDMENT AND REPLY TO ACTION PURSUANT TO 37 CFR § 1.111

This paper is a Reply to the Action dated October 17, 2005 pursuant to 37 C.F.R. § 1.111 in connection with the above-identified patent application. Applicants respectfully request that the application be amended, without prejudice, as follows:

- 図 Amendments to the claims begin on page 2 of this paper.
- X Remarks/Arguments begin on page 19 of this paper.